Evidence map›Paper›PMID 24682222›Full record

ArticleJAMA2014

The new cholesterol and blood pressure guidelines: perspective on the path forward.

Harlan M Krumholz

Abstract readEditorialComment
In one paragraph

Article in JAMA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Caring for patients with kidney disease: shifting the paradigm from evidence-based medicine to patient-centered care.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2016
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Aspirin for primary prevention: what's a clinician to do?Journal of general internal medicine · 2015
    Article
  12. Article
  13. Dialysis: destination or journey.Journal of the American Society of Nephrology : JASN · 2014
    Article
  14. [Not Available].The Canadian journal of hospital pharmacy · 2014
    Article
  15. Can I get a guideline to help me interpret treatment guidelines?The Canadian journal of hospital pharmacy · 2014
    Article
  16. Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Harlan M KrumholzRobert Wood Johnson Foundation Clinical Scholars Program, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, Department of Health Policy and Management, Yale School of Public Health, and Center for Out.

Funding

Center for Cardiovascular Outcomes Research at Yale UniversityU01HL105270 · NHLBI · YALE UNIVERSITY · PI CURTIS, JEPTHA PELHAM, KRUMHOLZ, HARLAN MARC · 2010 to 2013
$5.8M
NHLBI NIH HHS U01 HL105270NHLBI NIH HHS U01 HL105270-04
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Practice Guidelines as TopicAntihypertensive AgentsAtherosclerosisCardiovascular DiseasesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionMaleRisk AssessmentAntihypertensive AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID24682222
PMCPMC5459388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.